Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Emerg Infect Dis ; 29(10): 2141-2144, 2023 10.
Article in English | MEDLINE | ID: mdl-37735754

ABSTRACT

Vibrio mimicus caused a seafood-associated outbreak in Florida, USA, in which 4 of 6 case-patients were hospitalized; 1 required intensive care for severe diarrhea. Strains were ctx-negative but carried genes for other virulence determinants (hemolysin, proteases, and types I-IV and VI secretion systems). Cholera toxin-negative bacterial strains can cause cholera-like disease.


Subject(s)
Cholera , Vibrio mimicus , Humans , Cholera/epidemiology , Florida/epidemiology , Vibrio mimicus/genetics , Disease Outbreaks , Seafood
2.
Oxf Med Case Reports ; 2021(10): omab104, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34729202

ABSTRACT

Polycythemia vera is a rare hematological disorder that can cause heart failure with reduced ejection fraction from chronic micro-vascular ischemia. Appropriately recognizing the underlying cause of cardiomyopathy is essential to decrease morbidity and mortality. Patients can present with elevated troponin level and have patent epicardial coronary arteries on coronary angiogram, hence presenting a diagnostic challenge for health care professionals. Furthermore, the presentation can mimic myocarditis. Herein, we report a case of a 61-year-old female who presented with heart failure due to microvascular thrombotic complication associated with polycythemia vera. Laboratory investigation and coronary angiogram were inconclusive. A high degree of clinical suspicion and utilizing non-invasive techniques, such as cardiac imaging, can describe myocardial pathology and aid with the diagnosis.

3.
BMJ Case Rep ; 14(6)2021 Jun 22.
Article in English | MEDLINE | ID: mdl-34158323

ABSTRACT

Adult-onset Still's disease (AOSD) is a rare inflammatory disorder affecting just over one in a million people. Due to its rarity, understanding of its pathophysiology and the spectrum of its clinical associations are limited. Improved case identification and creation of patient registries have begun to reveal sporadic reports of deep venous thromboses associated with AOSD. Herein, we report the first case of recurrent deep venous thrombosis in a patient with AOSD despite treatment with therapeutic dose anticoagulant medication. This case points for a judicious approach to the selection of an anticoagulation strategy for deep venous thromboses in the setting of active AOSD. This case is of contemporary interest in its clinical similarity with COVID-19 symptoms and pathophysiology for which a careful diagnostic approach with a broad differential should be considered given the limitations of SARS-CoV-2 testing and the risk associated with treatment in the event of misdiagnosis.


Subject(s)
COVID-19 , Still's Disease, Adult-Onset , Venous Thrombosis , Adult , COVID-19 Testing , Humans , SARS-CoV-2 , Still's Disease, Adult-Onset/complications , Still's Disease, Adult-Onset/diagnosis , Still's Disease, Adult-Onset/drug therapy , Venous Thrombosis/diagnosis , Venous Thrombosis/drug therapy , Venous Thrombosis/etiology
4.
6.
Am J Case Rep ; 19: 783-789, 2018 Jul 04.
Article in English | MEDLINE | ID: mdl-29970876

ABSTRACT

BACKGROUND Malignant pleural mesothelioma (MPM) is a highly lethal cancer with a median survival of ~12 months even with aggressive intervention. Frontline therapy relies on systemic cisplatin and pemetrexed chemotherapy and has a response rate of ~35-41%; currently, there are no US Food and Drug Administration approved second-line therapies for MPM. Herein, we present a patient with MPM who experienced rapid disease progression after standard therapy but who had an exceptional and sustained response to immune checkpoint inhibition with single agent nivolumab. CASE REPORT A 68-year-old male with a history of work-related asbestos exposure was diagnosed with MPM. He was treated with primary resection followed by systemic chemotherapy with cisplatin and pemetrexed. When chemotherapy failed, he was switched to immunotherapy with nivolumab and achieved an exceptional response. CONCLUSIONS We report the first case of a patient with MPM who experienced rapid disease progression after standard therapy but had an exceptional and sustained response to immune checkpoint inhibition with single agent nivolumab. As outcomes with traditional chemotherapy regimens remain disappointing, there is a substantial need for new approaches to MPM; our case highlights a new therapeutic opportunity even in the face of aggressive disease. Indeed, a new era of investigation utilizing immunotherapy for mesothelioma is beginning, with much anticipation.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Mesothelioma/drug therapy , Pleural Neoplasms/drug therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Humans , Immunotherapy , Male , Nivolumab , Treatment Outcome
7.
Ann Otol Rhinol Laryngol ; 126(4): 334-339, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28061634

ABSTRACT

INTRODUCTION: Advanced stage squamous cell carcinoma of the head and neck carries an overall poor prognosis, and survivorship gains have remained relatively stagnant compared to other malignancies due to its complex tumor biology and lack of proven effective targeting agents. METHODS: We present a case of an exceptional responder to molecular-targeted therapy for metastatic oropharyngeal squamous cell carcinoma using a chemotherapeutic agent FDA approved for breast cancer and targeting the HER2/Neu receptor in order to discuss the larger clinical implications. RESULTS: The National Cancer Institute (NCI) has recently instituted the Exceptional Responders Initiative in order to identify such patients with unexpected outcomes in order to expedite the development of additional targeted therapies. This case illustrates the opportunity for cure using targeted oncogene identification in a scenario of recurrent squamous cell carcinoma with lung metastasis typically considered fatal. CONCLUSIONS: Molecular tumor analysis is an infrequently utilized tool in head and neck squamous cell carcinoma; however, as understanding of biologic mechanisms improves, additional molecular targets will become available and expand treatment opportunities such as HER2/Neu targeting. The Exceptional Responders Initiative is a unique strategy with potential to expedite progress.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Lung Neoplasms/drug therapy , Neoplasm Recurrence, Local/drug therapy , Oropharyngeal Neoplasms/drug therapy , Precision Medicine , Trastuzumab/therapeutic use , Antineoplastic Combined Chemotherapy Protocols , Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/secondary , Cetuximab/administration & dosage , Chemoradiotherapy , Cisplatin/administration & dosage , Docetaxel , Fluorouracil/administration & dosage , Humans , Induction Chemotherapy , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Lymph Nodes/pathology , Magnetic Resonance Imaging , Male , Mediastinum , Middle Aged , Molecular Targeted Therapy , Oropharyngeal Neoplasms/diagnostic imaging , Oropharyngeal Neoplasms/metabolism , Oropharyngeal Neoplasms/pathology , Positron Emission Tomography Computed Tomography , Radiotherapy, Intensity-Modulated , Receptor, ErbB-2/metabolism , Taxoids/administration & dosage , Tomography, X-Ray Computed
8.
Gynecol Oncol Rep ; 10: 9-12, 2014 Dec.
Article in English | MEDLINE | ID: mdl-26075992

ABSTRACT

•We reported the first tuberous sclerosis patient with an ovarian yolk sac tumor.•Although angiomyolipoma is a common benign tumor in TS patients, abdominal malignancies must be considered.

9.
Ann Vasc Surg ; 27(5): 673.e1-4, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23602432

ABSTRACT

Neurofibromatosis type 1 is the most common inherited disorder of the nervous system, affecting approximately 1 in 3,000 people. A small but significant subset of these patients develop vasculopathies. We present the first reported case of neurofibromatosis type 1 presenting with obstructive jaundice secondary to multiple hepatic artery aneurysms. Therapy included staged coil embolization of the hepatic artery aneurysms and resection of a large retroperitoneal neurofibroma.


Subject(s)
Aneurysm/complications , Hepatic Artery , Jaundice, Obstructive/etiology , Neurofibromatosis 1/complications , Adolescent , Aneurysm/therapy , Humans , Jaundice, Obstructive/therapy , Male , Neurofibromatosis 1/therapy
10.
Postgrad Med J ; 89(1052): 340-5, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23389283

ABSTRACT

Meningococcal sepsis and purpura fulminans is a rare but highly lethal disease process that requires a multidisciplinary team of experts to optimise morbidity and mortality outcomes due to the breadth of complications of the disease. The surgical perspective involves the critical care management which utilises all currently available measured outcomes of critical care management as well as experimental therapies. Limb loss is common, and is reflective of the high incidence of compartment syndrome compounded by the significant soft tissue loss secondary to purpura and limb ischaemia, presumptively due to digital microemboli. A multidisciplinary approach involving current standards in critical care and early surgical evaluation are important in improving patient outcomes and limb salvage.


Subject(s)
Bacteremia/surgery , Critical Care/methods , Limb Salvage/methods , Meningococcal Infections/surgery , Purpura Fulminans/surgery , Skin/blood supply , Adult , Amputation, Surgical , Anti-Bacterial Agents/administration & dosage , Bacteremia/microbiology , Bacteremia/physiopathology , Female , Humans , Interdisciplinary Communication , Meningococcal Infections/complications , Meningococcal Infections/physiopathology , Purpura Fulminans/etiology , Purpura Fulminans/physiopathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...